Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: "Steven A Rosenberg" Clear advanced filters

  • Despite impressive clinical activity in B-cell lymphoma and melanoma, questions remain about the immunobiology of adoptive T-cell therapies.

    • Carl June
    • Steven A Rosenberg
    • Jeffrey S Weber
    Special Features
    Nature Biotechnology
    Volume: 30, P: 611-614

  • The adoptive transfer of autologous tumor-infiltrating lymphocytes is one of the most promising developments of recent years for the treatment of patients with solid tumors. In this Review, a pioneer of this method, Steven Rosenberg, outlines the history and current situation for this therapy and explains what clinicians need to know.

    • Steven A. Rosenberg
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 8, P: 577-585

  • T cells can be genetically modified to express chimeric antigen receptors (CARs) that target CD19, which is expressed by B cell malignancies, but not by normal tissues. This Review outlines the use of CARs in the treatment of these malignancies and states that it is likely to become an important therapy option for these patients.

    • James N. Kochenderfer
    • Steven A. Rosenberg
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 10, P: 267-276

  • Adoptive cell therapy (ACT), using either autologous tumour-infiltrating lymphocytes or donor lymphocytes, has proved an effective treatment for some patients with advanced cancers. Can the ability to genetically engineer human lymphocytes for ACT further expand the use of this treatment?

    • Steven A. Rosenberg
    • Nicholas P. Restifo
    • Mark E. Dudley
    Reviews
    Nature Reviews Cancer
    Volume: 8, P: 299-308

  • This article discusses how T cells promote antitumour immunity in patients with cancer. In certain cancer types, T cell populations that are isolated from tumours and expandedin vitrocan promote cancer remission when re-infused into patients. The authors explain the pros and cons of this type of immunotherapy.

    • Nicholas P. Restifo
    • Mark E. Dudley
    • Steven A. Rosenberg
    Reviews
    Nature Reviews Immunology
    Volume: 12, P: 269-281